Opinions Jim Cramer - Mad Money
Sarepta TherapeuticsSRPTDON'T BUYJan 15, 2025
Jim Cramer - Mad MoneyUnknown
$119.43
Stock price when the opinion was issued
$15.11
As of Jun 10, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
The RNA-based therapeutic companies are not doing well. Maybe it's a reverse-halo effect of the Moderna report. It's troubling.